

Supplementary Online Content

Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma: a phase 2 clinical trial. *JAMA Oncol*. Published online October 31, 2019.
doi:10.1001/jamaoncol.2019.3702

eFigure. Examples of Patients Downstaged to Surgery

eTable 1. Reasons for Unresectability of Patients Finally Resected

eTable 2. Cox Regression Analysis of Overall Survival According to Baseline Characteristics

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure 1: Examples of Patients Downstaged to Surgery

73-year old male patient with a right hemiliver tumor in contact with the left portal vein (A). At 6 months, partial response by RECIST and CHOI criteria, and no contact with the left portal vein (B). He was treated with extended right hepatectomy, achieving R0 resection. He recurred after 1 year at the resection site, which was treated with stereotactic radiotherapy, but with recent progression of the same lesion. He is alive at 45 months following diagnosis and 32 months following surgery.

56-year old female patient with left hemiliver tumor involving left portal vein up to the portal trunk (C). At 6 months, stable disease by RECIST 1.1, partial response by CHOI, with thrombosis stabilized (D). She was treated with extended left hepatectomy. She recurred with one solitary tumor at 1 year following surgery in the right liver, treated with radiofrequency ablation. She is alive with no evidence of disease at 33 months following diagnosis, 25 months following surgery and 13 months following radiofrequency.



eTable 1: Reasons for Unresectability of Patients Finally Resected

Patient number	Reason for initial unresectability	Outcomes following treatment	Surgical resection
4	Central lesion in contact with both left and right portal branches	Left portal branch free	Extended right hepatectomy
8	Central lesion in contact with both left and right portal branches, left portal vein thrombosis	Right portal branch free	Left hepatectomy extended to anterior sector
11	Right liver lesion with contact with left portal branch	Left portal branch free	Right hepatectomy
18	Left liver lesion with tumoral thrombus in the left branch up to the trunk	Necrosis of the thrombus	Left hepatectomy, viable tumor in the branch but R0 surgery
19	Central lesion in contact with both left and right portal branches, left portal vein thrombosis	Right portal branch free	Left hepatectomy extended to anterior sector
22	Central lesion in contact with both left and right portal branches	Right portal branch free	Left hepatectomy extended to anterior sector
26	Involvement of 3 hepatic veins	Left hepatic vein free	Extended right hepatectomy
30	Central lesion in contact with both left and right portal branches	Left hepatic branch free	Right hepatectomy
41	Involvement of 3 hepatic veins	Left hepatic vein free	Extended right hepatectomy

eTable 2: Cox Regression Analysis of Overall Survival According to Baseline Characteristics

	Univariable analysis		Multivariable (n=36)	
	HR [95%]	P value	HR [95%]	P value
Age (by 5-years increment), n=41	0.94 [0.75 - 1.16]	0,549		
Sex (male vs female), n=41	1.06 [0.45 - 2.49]	0,888		
Cirrhosis, n=41	1.82 [0.76 - 4.36]	0,179		
PS>1, n=40	1.85 [0.79 - 4.3]	0,155		
Albumin (by 5UI increment), n=39	0.32 [0.19 - 0.54]	<0.001	0.21 [0.11 - 0.43]	< 0.001
Prothrombin time, n=41	0.91 [0.79 - 1.04]	0,148		
Total bilirubin, n=41	1.25 [0.92 - 1.71]	0,16		
ALT, n=41	0.9 [0.68 - 1.18]	0,439		
AST, n=41	1.14 [0.8 - 1.61]	0,474		
PAL (by 10UI increment), n=41	1.08 [1.03 - 1.13]	0,002		

GGT (by 10UI increment), n=40	1.02 [1 - 1.04]	0,056		
AFP> ULN, n=40	2.31 [0.99 - 5.39]	0,052		
CA19.9> ULN, n=39	1.78 [0.72 - 4.39]	0,21		
CEA> ULN, n=39	3.27 [1.36 - 7.86]	0,008	5.17 [1.82 - 14.69]	0,002
Previous surgery, n=41	0.49 [0.11 - 2.11]	0,336		
Bilolateral tumor, n=41	1.55 [0.67 - 3.6]	0,306		
Pulmonary lesions, n=41	1.5 [0.55 - 4.09]	0,423		
Abdominal lymph nodes, n=41	2.33 [0.95 - 5.69]	0,063		
Liver hilar lymph nodes, n=41	1.84 [0.74 - 4.57]	0,186		
Other centers vs coordinating center, n=41	2.62 [1.1 - 6.29]	0,03		

PS: Performance Status; ALT: Alanin Transferase; AST: Aspartate Transferase; GT: Glutamyl Transferase; PAL: Alkalin Phosphatase; AFP: Alpha-feto Protein; CA: Carcino Antigen; CEA: Carcino-Embryonic Antigen.

